| NCT06077864A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) | Survodutide Obesity / overweight | BMI ≥27 · Established CVD | Ph 3 | Active, not recruiting | 540 | May 2026 | 1 | |
| NCT06632444LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Survodutide MASH / NAFLD / liver fibrosis, Obesity / overweight | — | Ph 3 | Recruiting | 526 | Dec 2031 | — | |
| NCT06632457LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Survodutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥27 | Ph 3 | Recruiting | 444 | Jun 2029 | — | |
| NCT04771273A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) | Survodutide MASH / NAFLD / liver fibrosis | — | Ph 2 | Completed | 154 | Nov 2023 | 1 | results |
| SYNCHRONIZE™-2A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight | Survodutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Completed | 143 | Dec 2025 | 1 | |
| SYNCHRONIZE™-1A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Survodutide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 118 | Dec 2025 | 1 | |
| NCT04153929A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. | Semaglutide, Survodutide Obesity / overweight, Type 2 diabetes | BMI 25-50 | Ph 2 | Completed | 80 | Oct 2021 | 1 | results |
| NCT04667377A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight | Survodutide Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 43 | Sep 2022 | 2 | results |
| NCT06309992A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) | Survodutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 37 | Oct 2025 | 1 | |
| SYNCHRONIZE™JPA Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease | Survodutide Obesity / overweight | HbA1c ≥6.5% | Ph 3 | Completed | 28 | Dec 2025 | 1 | |
| NCT06214741A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight | Survodutide Obesity / overweight | BMI ≥28 | Ph 3 | Completed | 28 | Jul 2025 | — | |
| NCT05296733A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906 | Survodutide Healthy volunteers, Hepatic impairment, Obesity / overweight | BMI 18.5-40 | Ph 1 | Completed | 13 | Dec 2023 | 1 | |
| NCT06352411A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems | Survodutide Healthy volunteers, Renal impairment | BMI 20-40 | Ph 1 | Completed | 2 | Sep 2025 | — | |
| NCT03591718A Study to Test Different Doses of BI 456906 in Patients With Obesity | Survodutide Obesity / overweight | BMI 27-40 | Ph 1 | Completed | 2 | Apr 2020 | 1 | |
| NCT06745284A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity | Semaglutide, Survodutide Obesity / overweight | BMI 30-45 | Ph 1 | Active, not recruiting | 2 | Jan 2027 | — | |
| NCT07221591A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body | Survodutide Healthy volunteers, Obesity / overweight | BMI 27-39.9 | Ph 1 | Active, not recruiting | 2 | Aug 2026 | — | |
| NCT06564441A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity | Survodutide Healthy volunteers, Obesity / overweight | BMI 27-39.9 | Ph 1 | Completed | 1 | Dec 2025 | — | |
| NCT07413913A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector | Survodutide Healthy volunteers, Obesity / overweight | BMI 22-39.9 | Ph 1 | Active, not recruiting | 1 | May 2026 | — | |
| NCT07071974A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body | Survodutide Healthy volunteers | BMI 18.5-29.9 | Ph 1 | Completed | 1 | Oct 2025 | — | |
| NCT05751226A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 | Semaglutide, Survodutide Obesity / overweight | BMI 27-40 | Ph 1 | Completed | 1 | Aug 2024 | — | |
| NCT07407348A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body | Survodutide Obesity / overweight | BMI 27-39.9 | Ph 1 | Recruiting | 1 | Jan 2027 | — | |
| NCT06492135A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body | Survodutide Obesity / overweight | BMI ≥30 | Ph 1 | Completed | 1 | Apr 2025 | — | |
| NCT06772532A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body | Survodutide Healthy volunteers | BMI 20-29.9 | Ph 1 | Completed | 1 | May 2025 | — | |
| NCT03175211Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers | Survodutide Healthy volunteers | BMI 20-29.9 | Ph 1 | Completed | 1 | Feb 2018 | 1 | |
| NCT05421338A Study in Healthy Men to Test How BI 456906 is Processed in the Body | Survodutide Healthy volunteers, Obesity / overweight | Male · Healthy volunteers | Ph 1 | Completed | 1 | Nov 2022 | — | |
| NCT05202353A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver | Semaglutide, Survodutide Obesity / overweight | BMI 30-40 | Ph 1 | Recruiting | 1 | Dec 2026 | — | |
| NCT06200467A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity | Survodutide Healthy volunteers, Obesity / overweight | BMI 27-39.9 | Ph 1 | Completed | 1 | Oct 2025 | — | |
| NCT04384081A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2 | Survodutide Healthy volunteers, Obesity / overweight | BMI 23-40 | Ph 1 | Completed | 1 | Nov 2020 | — | |
| NCT05896384A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood | Survodutide Healthy volunteers, Obesity / overweight | BMI 27-40 | Ph 1 | Completed | 1 | Feb 2025 | — | |
| NCT06352424A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity | Survodutide Obesity / overweight | BMI 27-40 | Ph 1 | Completed | 1 | Feb 2025 | — | |
| ARTIST-CKDAlbuminuria Reduction Study With Survodutide Treatment in Kidney Disease | Survodutide Chronic kidney disease | BMI ≥21 | Ph 2 | Not yet recruiting | 0 | Nov 2027 | — | |
